TD Asset Management Inc Sells 6,348 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

TD Asset Management Inc decreased its position in 10x Genomics, Inc. (NASDAQ:TXG) by 4.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 137,982 shares of the company’s stock after selling 6,348 shares during the quarter. TD Asset Management Inc’s holdings in 10x Genomics were worth $7,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of TXG. BlackRock Inc. lifted its position in 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock valued at $696,572,000 after purchasing an additional 1,138,358 shares during the last quarter. Baillie Gifford & Co. lifted its position in 10x Genomics by 1.8% in the first quarter. Baillie Gifford & Co. now owns 8,753,987 shares of the company’s stock valued at $488,385,000 after purchasing an additional 151,752 shares during the last quarter. Vanguard Group Inc. lifted its position in 10x Genomics by 5.7% in the third quarter. Vanguard Group Inc. now owns 8,274,359 shares of the company’s stock valued at $235,654,000 after purchasing an additional 446,601 shares during the last quarter. FMR LLC lifted its position in 10x Genomics by 36.5% in the first quarter. FMR LLC now owns 4,372,294 shares of the company’s stock valued at $243,930,000 after purchasing an additional 1,169,928 shares during the last quarter. Finally, Sands Capital Management LLC lifted its position in 10x Genomics by 16.6% in the first quarter. Sands Capital Management LLC now owns 3,737,768 shares of the company’s stock valued at $208,530,000 after purchasing an additional 530,985 shares during the last quarter. Institutional investors own 79.16% of the company’s stock.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 2,000 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $49.37, for a total value of $98,740.00. Following the sale, the chief executive officer now directly owns 862,093 shares of the company’s stock, valued at $42,561,531.41. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.65% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Barclays lowered their price objective on 10x Genomics from $66.00 to $47.00 and set an “overweight” rating for the company in a research report on Friday, September 29th. Citigroup boosted their target price on 10x Genomics from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Canaccord Genuity Group reissued a “buy” rating and set a $70.00 target price on shares of 10x Genomics in a research note on Tuesday, September 19th. Finally, Morgan Stanley reissued an “overweight” rating and set a $65.00 target price on shares of 10x Genomics in a research note on Monday, August 7th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $60.78.

10x Genomics Stock Up 3.0 %

Shares of TXG stock opened at $43.42 on Tuesday. The stock has a market cap of $5.13 billion, a price-to-earnings ratio of -22.73 and a beta of 1.84. The business’s fifty day moving average is $40.46 and its 200 day moving average is $49.52. 10x Genomics, Inc. has a twelve month low of $31.28 and a twelve month high of $63.57.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.